ÂÜÀòÂÒÂ×

Mario R. Mautino has a strong background in the pharmaceutical industry, with extensive experience in drug discovery and development. Mario R. is currently serving as the Chief Scientific Officer at ³§²â²Ô³¦°ù´Ç³¾³Ü²Ô±ðâ„¢ since December 2020. Prior to this, they worked as a Principal Consultant & Founder at PharmaWay Consulting, where they provided support on all stages of small molecule, biologics, or gene therapy drug discovery.

Before their role at PharmaWay Consulting, Mario held various senior leadership positions at ImmunSYS, Inc. and NewLink Genetics. At ImmunSYS, Inc., they served as the Executive Vice President Chemistry Manufacturing and Controls from April 2020 to September 2020. At NewLink Genetics, they held multiple roles, including Senior VP Research and Development, Intellectual Property Officer, Senior VP of Drug Discovery, VP of Drug Discovery, and Sr Scientist. Mario R.'sresponsibilities included managing CMC activities, supervising non-clinical studies, leading research projects, and obtaining patents for inventions.

Prior to their industry roles, Mario worked as a Post-Doctoral Fellow at the National Institutes of Health, where they contributed to the development of HIV-based lentiviral vectors for gene therapy. Mario R. also worked as a Post-Doctoral Fellow at Universidad Nacional de Cordoba, where they conducted research in molecular biology.

Overall, Mario R. Mautino's work experience revolves around drug discovery and development, with a focus on CMC activities, non-clinical studies, research leadership, and intellectual property management.

Mario R. Mautino completed their education at the Universidad Nacional de Córdoba. From 1986 to 1990, they pursued studies in Biological Chemistry. Subsequently, from 1990 to 1995, they obtained a Ph.D. in Molecular Genetics from the same university.